Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, et al.
Neuropharmacology (2018) Vol. 142, pp. 143-166
Open Access | Times Cited: 267

Showing 1-25 of 267 citing articles:

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
Alan K. Davis, Frederick S. Barrett, Darrick G. May, et al.
JAMA Psychiatry (2020) Vol. 78, Iss. 5, pp. 481-481
Open Access | Times Cited: 924
Psychedelics and Psychedelic-Assisted Psychotherapy
Collin Reiff, Elon E. Richman, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2020) Vol. 177, Iss. 5, pp. 391-410
Closed Access | Times Cited: 446
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Matthew W. Johnson, Peter S. Hendricks, Frederick S. Barrett, et al.
Pharmacology & Therapeutics (2018) Vol. 197, pp. 83-102
Closed Access | Times Cited: 420
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 2, pp. 151-158
Open Access | Times Cited: 296
Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
Natalie Hesselgrave, Timothy A. Troppoli, Andreas B. Wulff, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 17
Open Access | Times Cited: 259
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Albert Garcia‐Romeu, Alan K. Davis, Fire Erowid, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1088-1101
Closed Access | Times Cited: 222
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Anne Katrin Schlag, Jacob S. Aday, Iram Salam, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 3, pp. 258-272
Open Access | Times Cited: 220
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
Simone B. Sartori, Nicolas Singewald
Pharmacology & Therapeutics (2019) Vol. 204, pp. 107402-107402
Open Access | Times Cited: 205
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study
B. Anderson, Alicia Danforth, Prof Robert Daroff, et al.
EClinicalMedicine (2020) Vol. 27, pp. 100538-100538
Open Access | Times Cited: 202
Long-term effects of psychedelic drugs: A systematic review
Jacob S. Aday, Cayla M. Mitzkovitz, Emily K. Bloesch, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 113, pp. 179-189
Closed Access | Times Cited: 183
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Erwin Krediet, Tijmen Bostoen, Joost J. Breeksema, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 23, Iss. 6, pp. 385-400
Open Access | Times Cited: 181
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Leor Roseman, Lysia Demetriou, Matthew B. Wall, et al.
Neuropharmacology (2017) Vol. 142, pp. 263-269
Open Access | Times Cited: 179
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
Kim P. C. Kuypers, Livia Ng, David Erritzøe, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1039-1057
Open Access | Times Cited: 168
The Therapeutic Potential of Psilocybin
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
Molecules (2021) Vol. 26, Iss. 10, pp. 2948-2948
Open Access | Times Cited: 153
Case analysis of long-term negative psychological responses to psychedelics
Rebecka Bremler, Nancy Katati, Parvinder Shergill, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 42
Psychiatric risks for worsened mental health after psychedelic use
Alessia Marrocu, Hannes Kettner, Brandon Weiss, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 3, pp. 225-235
Open Access | Times Cited: 16
The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials
Lavinia Hogea, Dana Cătălina Tabugan, Iuliana Costea, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 278-278
Open Access | Times Cited: 2
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Thomas Anderson, Rotem Petranker, Daniel Rosenbaum, et al.
Psychopharmacology (2019) Vol. 236, Iss. 2, pp. 731-740
Closed Access | Times Cited: 132
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey
Albert Garcia‐Romeu, Alan K. Davis, Earth Erowid, et al.
Frontiers in Psychiatry (2020) Vol. 10
Open Access | Times Cited: 112
Ethics and ego dissolution: the case of psilocybin
William Smith, Dominic A. Sisti
Journal of Medical Ethics (2020) Vol. 47, Iss. 12, pp. 807-814
Open Access | Times Cited: 102
Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases—A Systematic Review and Meta-Analysis of Clinical Trials
Ana Sofia Vargas, Ângelo Luís, Mário Barroso, et al.
Biomedicines (2020) Vol. 8, Iss. 9, pp. 331-331
Open Access | Times Cited: 99
Psychedelic microdosing benefits and challenges: an empirical codebook
Thomas Anderson, Rotem Petranker, Adam Christopher, et al.
Harm Reduction Journal (2019) Vol. 16, Iss. 1
Open Access | Times Cited: 97
Chronic pain and psychedelics: a review and proposed mechanism of action
Joel Castellanos, C. Leonard Woolley, Kelly Bruno, et al.
Regional Anesthesia & Pain Medicine (2020) Vol. 45, Iss. 7, pp. 486-494
Closed Access | Times Cited: 89
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 8-21
Open Access | Times Cited: 81
Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review
Kristin Heuschkel, Kim P. C. Kuypers
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 73
Page 1 - Next Page

Scroll to top